Hopewell Therapeutics is discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We are pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry leading companies. We are developing our own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.
External link for Hopewell Therapeutics, Inc.
216 W Cummings Park
Woburn, Massachusetts 01801, US
Hopewell Therapeutics, Inc. reposted this
We’re pleased to be included in a BioCentury Inc. article highlighting the strong potential of ionizable lipids in the #LNP space. Thank you BioCentury for featuring Hopewell and speaking with our Chief Scientific Officer, Kate Zhang, about our novel approach to developing tissue-targeted LNPs for delivery of #genomicmedicines. Read the full article: https://bit.ly/3W7AN98
We’re pleased to be included in a BioCentury Inc. article highlighting the strong potential of ionizable lipids in the #LNP space. Thank you BioCentury for featuring Hopewell and speaking with our Chief Scientific Officer, Kate Zhang, about our novel approach to developing tissue-targeted LNPs for delivery of #genomicmedicines. Read the full article: https://bit.ly/3W7AN98
Hey #ASGCT attendees in Baltimore! Check out our poster (#1273) today to delve into the data and exciting findings regarding tissue-targeted lipid nanoparticles delivering mRNA in pulmonary, oncology, and vaccine programs. Our colleagues Kate Zhang and Xin Kai will be there to greet you at the poster session! #ASGCT2024 #LNPs #genomicmedicine #immunotherapy #cancervaccines #biotechnology
Hopewell Therapeutics, Inc. will be at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting this week in Baltimore, MD! Please join us at our poster session on May 9, where we will present Hopewell’s tissue-targeted lipid nanoparticles delivering mRNA with promising results in pulmonary, oncology, and vaccine programs. Dr. Kate Zhang, our CSO, and Dr. Xin Kai, our Director of Discovery Biology will present at the poster session on Saturday, May 9th at 12:00 p.m. ET in Exhibit Hall | Abstract 1273 Read our press release today: https://lnkd.in/eBTys8ax #ASGCT2024 #LNPs #genomicmedicine #immunotherapy #cancervaccines #biotechnology
Hopewell Therapeutics, Inc. reposted this
In 2023, our Venture Capital & Emerging Companies team including Members Daniel DeWolf, Samuel Effron, and Jeremy G. completed 130 transactions for a variety of emerging companies, with a total deal value of more than $2.6 billion. Some of the largest transactions of 2023 include: - Our representation of Gradiant in its Series D financing bringing their total funding to $400 million. - Mintz’s advisement of Hopewell Therapeutics, Inc. in its seed financing of $25 million. -The team’s representation of Revelstoke Security in its $20 million Series B financing and later sale to Arctic Wolf. For more information on Mintz’s Venture Capital Practice click here. https://bit.ly/3T1Vrak
Congratulations to Hopewell Therapeutics, Inc.'s founder and Chief Technology Officer, Qiaobing Xu, on being named a Senior Member of the National Academy of Inventors. Dr. Xu's extensive pioneering research at Tufts University serves as the foundation for Hopewell's novel tissue-targeted lipid nanoparticle platform and therapeutic programs. #hopewell #lnp #lipidnanoparticles #tufts https://lnkd.in/gr2wQRE9
Hopewell Therapeutics, Inc. will be at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting in San Diego this week! Please join us at our oral and poster sessions on November 4, where we will present Hopewell’s proprietary tissue targeted LNPs delivering mRNA encoding Bispecific T-cell engagers (BiTE) that demonstrate potent antitumor effects on both hematological and solid tumor models. Dr. Xin Kai, our Director of Discovery Biology will deliver an oral presentation in Session 205b | Rapid Oral Abstract-Clinical on Saturday, November 4th at 12:40 p.m. PDT in Exhibit Hall C. Abstract 1358: “Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors” Read the abstract today: https://t.ly/P-9se Make sure to reach out to our team onsite to discuss further! #sitc2023 #LNP #ttLNP #BiTE #Immunotherapy #immunooncology